You're viewing a free preview.You're viewing a free preview — a sample of each dataset.

Clinical Trials

Longevity science and aging research trials by phase, sponsor, status and indication.

1,144 clinical trials tracked

Trial	Sponsor	Phase	Status	Start
Phase 2 MINDFuL: XPro1595 in Early Alzheimer's Disease With Inflammation	INmune Bio	Phase 2	Completed	—
Study of COYA 302 for the Treatment of ALS (ALSTARS)	Coya Therapeutics	Phase 2	Recruiting	—
Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease (NOPARK)	—	Phase 3	Completed	05/06/20
Biased G Protein-Coupled Receptor Kinase Signaling Via Beta2-Adrenergic Receptors and Downstream Activation of Protein Synthesis-Regulating Kinases and Receptor Desensitization in Human Skeletal Muscle	University of Copenhagen (Morten Hostrup)	Phase 2	Active, not recruiting	02/19/26
RESET: Phase 2a Study of JOTROL (Micellar Trans-Resveratrol) in Parkinson's Disease	Jupiter Neurosciences	Phase 2	Recruiting	—
PIONEER-ALS: Phase 1/2 Open-Label Dose-Escalation Study of VTx-002 in Adults With Amyotrophic Lateral Sclerosis	VectorY Therapeutics	Phase 1/Phase 2	Recruiting	—
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults	UConn Health	Phase 2	Recruiting	10/07/24
Targeting Oxidative Stress to Prevent Vascular and Skeletal Muscle Dysfunction During Disuse	Joel Trinity	NA	ACTIVE_NOT_RECRUITING	09/01/19
Cognition, Age, and Rapamycin Effectiveness - Downregulation of the mTOR Pathway (CARPE DIEM)	UT Health San Antonio	Phase 1	Completed	—
Rapamycin - Effects on Alzheimer's and Cognitive Health (REACH)	The University of Texas Health Science Center at San Antonio	Phase 2	Active, not recruiting	08/01/21

Showing 10 of 1,144 clinical trials

Peek at other modules

Daily longevity science headlines — aging research, deals, trials, and policy — with AI summaries.

The longevity science company universe by segment, stage, geography and capital raised.

Every disclosed longevity science round — size, stage and the investors behind it.

Who is joining, leaving and founding across longevity science and aging research.

Peer-reviewed aging research distilled into investor-relevant takeaways.

FDA, EMA and policy developments that move aging research and the longevity market.